“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande’s shift from a16z’s biotech arm to the leaner, AI-native VZVC signals a fascinating recalibration within the venture capital landscape, and one with profound implications for the future of AI in medicine. His perspective, articulated in the recent interview, highlights a crucial transition: biology moving from a science primarily focused on discovery to one increasingly driven by engineering principles. This isn’t merely a semantic shift; it’s a fundamental change in how problems are approached and solved, and it directly informs the types of investments that will yield the greatest returns. The conversation around who controls AI's direction, as explored in At TechBBQ, Europe’s AI conversations kept coming back to: Who’s actually in control?, resonates here; Pande’s emphasis on open datasets suggests a desire to avoid the proprietary data silos that can stifle innovation and limit AI's potential. This contrasts with the often-closed nature of pharmaceutical research, and underscores the need for a more collaborative approach to unlock the true power of AI in this sector. Furthermore, the ongoing discussion of where to submit statistical and probabilistic machine learning research, as detailed in [Where to submit stat/prob ML [D]]( /post/where-to-submit-stat-prob-ml-d-cmtebytq50uwjmi9zxx89w3px), demonstrates the growing need for robust evaluation and validation of AI models, particularly in high-stakes fields like medicine.

Pande’s decision to “bet small” – focusing on a more limited number of investments – is a deliberate strategy born from a realistic assessment of the challenges. He’s not chasing the fleeting hype of “revolutionary” AI solutions; instead, he’s acknowledging the persistent, brutally expensive reality of clinical trials. The cost and complexity of these trials remain significant barriers to translating AI-driven insights into tangible therapies. His focus on open datasets is particularly insightful. Walled-off, proprietary data, while seemingly valuable in the short term, ultimately limit the ability of AI to generalize and learn effectively. Shared datasets, rigorously curated and accessible to a broader community of researchers, offer a pathway to accelerating discovery and validating AI models across diverse populations, moving beyond the limitations of individual institutions. This echoes a broader trend towards open science and collaborative innovation, recognizing that collective intelligence often outperforms isolated efforts. The exploration of concepts like world models, as discussed in [WTF is a World Model? [D]]( /post/wtf-is-a-world-model-d-cmtebxwpf0uuzmi9z8sd7h0js), provides a glimpse into the future of AI – a future where models can understand and predict complex systems with increasing accuracy, crucial for navigating the intricacies of biological processes.

The shift towards an "engineering" mindset in biology, coupled with Pande’s focus on smaller, more strategic investments, represents a pragmatic and ultimately more sustainable approach to leveraging AI. It’s a recognition that AI isn't a magic bullet, but a powerful tool that requires careful calibration and application within a complex and highly regulated environment. The traditional venture capital model, often characterized by a "spray and pray" approach with numerous high-risk, high-reward bets, may not be ideally suited to the nuanced challenges of AI-driven drug discovery. Pande’s methodology suggests a preference for deep expertise, rigorous validation, and a commitment to open collaboration—a far cry from the hype-driven cycles that often characterize the tech industry. This isn’t about abandoning ambition; it’s about focusing resources on initiatives with the highest probability of success and the greatest potential for long-term impact.

Looking ahead, the question isn’t simply whether AI *can* transform medicine, but rather *how* we structure the ecosystem to ensure that transformation is equitable, accessible, and ultimately beneficial to patients. Pande’s emphasis on open datasets and a more engineering-focused approach suggests a path towards a more collaborative and sustainable future for AI in healthcare. The challenge now lies in fostering the infrastructure and incentives needed to support this model, breaking down the existing silos and encouraging the sharing of knowledge and resources across the research community. Will the pharmaceutical industry embrace this shift, or will the inherent pressures of profitability continue to drive a preference for proprietary data and closed innovation? The answer to that question will largely determine the trajectory of AI’s impact on medicine for years to come.